- Deutsche Bank has increased its price target for Acadia Pharmaceuticals to $38.00, suggesting a potential upside of 25.37%.
- The European Commission recently approved Daybu (trofinetide) for Rett syndrome, significantly expanding its market reach across the EU and other European countries.
- New prescriptions for Nuplazid, Acadia Pharmaceuticals’ Parkinson’s treatment, have seen a 20% year-over-year increase in the latest quarter.
An analyst at Deutsche Bank has increased their price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $38.00. Acadia Pharmaceuticals is a biopharmaceutical company that focuses on developing and selling new medicines to treat central nervous system disorders. Its main products include Daybu for Rett syndrome and Nuplazid for Parkinson’s disease psychosis.
The new price target suggests a potential upside of 25.37% from the stock’s trading price of $30.31 at the time of the report. An upside is the potential increase in a stock’s price, which shows how much an analyst believes it could grow. This positive outlook reflects recent company developments for Acadia Pharmaceuticals.
A key factor is the recent European Commission approval for Daybu (trofinetide), as highlighted by Businesswire. This makes Daybu the first and only approved treatment for Rett syndrome in the European Union. The approval covers adults and pediatric patients aged five years and older, marking a major regulatory achievement for Acadia Pharmaceuticals.
This approval allows Acadia Pharmaceuticals to sell Daybu across all 27 EU member states, plus Iceland, Liechtenstein, and Norway. This significantly expands the drug’s commercial reach and supports the long-term growth of the company’s rare disease business. The decision was supported by data from the successful LAVENDER study.
As highlighted by MarketBeat, Acadia Pharmaceuticals is also focused on its commercial strategy for Daybu and Nuplazid. This includes educating doctors and raising disease awareness. The company notes that new prescriptions for Nuplazid, its Parkinson’s treatment, have increased by 20% year over year in the most recent quarter.
